Fischer Medical Ventures outlined its strategic expansion across radiology, preventive healthcare, and wellness solutions in a shareholder letter dated September 16, 2026. The company highlighted international deployments in Indonesia and the Philippines alongside a significant capital infusion by its promoter group.

The promoter group converted warrants and subscribed to a preferential allotment, injecting approximately ₹59.67 crore into the company. This transaction increased promoter shareholding from 62.15% to 63.08%. Fischer Medical Ventures organized its business into three segments: Radiology, Preventive Healthcare, and Wellness Solutions. The Radiology segment remains the largest, featuring proprietary imaging technology developed in-house over 15 years.

International Expansion

Fischer Medical Ventures entered the Indonesian market in October 2024 with its 4T4TB solution for tuberculosis detection. This integrated workflow combines portable digital X-ray systems with AI-assisted image analysis and the FMV Prime qPCR platform. The initiative supports Indonesia’s National Stop Tuberculosis Programme, which targets elimination by 2030. In the Philippines, subsidiary Time Medical Philippines Inc. installed its first open MRI at Bulacan Medical Centre in November 2025. The facility uses the PICA Open MRI system, chosen for its helium-free design and teleradiology capabilities.

Preventive Healthcare and Wellness

Through wholly owned subsidiary FlynnCare, the company offers AI-enabled screening via MIDAS kiosks and the LIVE Dx tele-diagnosis platform. A province-wide deployment in Catanduanes integrates Health Kiosks with the PhilHealth-accredited FlynnCare Clinical Management System. The Wellness Solutions segment plans to launch AI-powered Integrated Rehabilitation Centers in Malaysia, aiming for 20 centers over two years. Additionally, Fischer Medical Ventures strengthened its collaboration to bring Vecura, an AI-enabled molecular research platform, to India to support drug discovery.

What the Numbers Show

The promoter capital infusion of ₹59.67 crore resulted in a modest increase in holding from 62.15% to 63.08%. This suggests the primary objective was strengthening the balance sheet rather than significant equity dilution or control consolidation. The simultaneous rollout of hardware in Southeast Asia and software-led screening models indicates a strategic pivot toward diversified revenue streams beyond traditional imaging sales.

Fischer Medical Ventures Limited appointed David Yeow as an additional independent director effective September 3, 2026. The company also announced September 22, 2026, as the record date for its 33rd Annual General Meeting and dividend entitlement.

The Board of Directors approved these governance updates in a meeting held on September 3, 2026. The appointment was made pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The record date intimation was issued under Regulation 42 of the same regulations.

Director Appointment Details

Mr. Yeow joins the board for a first term of five consecutive years, subject to shareholder approval. He is not liable to retire by rotation. The Singapore-based engineer brings over three decades of experience in manufacturing, quality systems, and global supply chain management.

He holds a Diplôme d'Ingénieur in Electronic Engineering from the École Nationale Supérieure d'Électronique et de Radioélectricité de Bordeaux and is a GE-certified Six Sigma Blackbelt. Previously, he held senior leadership roles at GE Plastics, Lanxess, and NTUitive. He currently serves as Principal at Hunniwell Lake Ventures, a medical device venture capital firm.

Audit Committee Reconstitution

Following the new appointment, the Board reconstituted the Audit Committee. The committee now comprises seven members, including four independent directors, one executive director, and one whole-time director.

AGM Scheduling and Record Dates

The company will hold its 33rd Annual General Meeting on Tuesday, September 29, 2026, at 11:00 am through video conferencing or other audio-visual means. M/s Nuren Lodaya & Associates Practising Company Secretary has been appointed as the scrutinizer for the e-voting process.

The Register of Members and Share Transfer Books will remain closed from September 23, 2026, to September 29, 2026, inclusive. This closure facilitates the AGM proceedings.

Tuesday, September 22, 2026, is the cut-off date for determining voting rights for e-voting on resolutions listed in the AGM notice and for dividend entitlement. The cut-off date for determining shareholders entitled to receive the dispatch of the AGM notice was September 4, 2026.

The e-voting period commences on Saturday, September 26, 2026, at 9:00 am and ends on Monday, September 28, 2026, at 5:00 pm. The Annual Report along with the notice of AGM has been dispatched to all eligible shareholders on September 7, 2026, through email and a letter containing the web link to those shareholders whose email ID is not registered with the Company or the RTA.